过敏与治疗杂志

抽象的

New Pharmacological Targets for Asthma Drug Development

Carla Máximo Prado, Renato Fraga Righetti, Patricia Angeli da Silva Pigati, Samantha Souza Possa, Anelize Sartori Alves dos Santos, Nathalia Montouro Pinheiro, Alessandra Choqueta de Toledo, Edna Aparecida Leick, Mílton de Arruda Martins and Iolanda de Fátima Lopes Calvo Tibério

Asthma is an inflammatory disorder characterized by airway hyperresponsiveness, followed by inflammation, remodeling and oxidative stress in the respiratory system and lung tissue. While glucocorticosteroids remain the gold-standard of asthma therapy, they have limitations because of their potentially severe adverse effects and the presence of corticosteroid resistance in some patients. In the present review we will focus in four main groups of experimental pharmacological approaches for future asthma and hyperresponsiveness treatment: proteinase inhibitors and flavonoids, arginase and iNOS inhibition, Rho-kinase inhibitors, cholinergic anti-inflammatory system and nicotinic receptors.